[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
11. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Loredo-Pozos G, Chiquete E, Oceguera-Villanueva A, Panduro A, Siller-López F, Ramos-Márquez ME: Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates. Med Oncol; 2009;26(3):269-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
  • Low BRCA1 gene expression is associated with increased invasiveness and influences the response of breast carcinoma (BC) to chemotherapeutics.
  • Women aged < or = 35 years (24%) had more family history of cervical cancer, stage III/IV disease, HER-2 positivity, and lower BRCA1 expression than older women (P < 0.05).
  • After multivariate analysis, only disease stage explained BRCA1 mRNA levels in the lowest quartile.
  • Low BRCA1 mRNA expression is associated mainly with younger ages and advanced clinical stage of premenopausal BC.


13. Sinha S, Sinha N, Bandyopadhyay R, Mondal SK: Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading. J Cytol; 2009 Oct;26(4):140-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading.
  • BACKGROUND: Cytological grading (CG) on aspirates of breast carcinoma is a useful tool for surgical maneuver and prognosis.
  • AIMS: An endeavor was made to use CG on aspirates of breast carcinoma using Robinson's grade and to correlate it with Bloom Richardsons' histopathological grading.
  • MATERIALS AND METHODS: A total of 59 patients of breast carcinoma, aged 28-57 years, were aspirated and the smears were graded using Robinson's criteria.
  • For grade I and II tumors, there was substantial strength of agreement between cytology and histopathology, while in grade III, the concordance was nearly perfect.
  • Lymph node metastasis was observed in three with cytological grade II, 28 of grade III and none of grade I.
  • All grade I had stage A, two of grade II had stage B, while all grade III had either stage B or stage C disease.
  • CONCLUSIONS: Thus, CG of breast carcinoma correlates well with histopathological grading and may well be useful as a prognostic marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Quant Cytol Histol. 1987 Dec;9(6):480-4 [2829937.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):947-9 [7909010.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):295-311 [9143822.001]
  • [Cites] Cancer. 1997 Feb 25;81(1):16-21 [9100536.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):260-5 [8575287.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):388-95 [8834313.001]
  • [Cites] Diagn Cytopathol. 1996 Aug;15(2):116-20 [8872432.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):203-8 [8050325.001]
  • (PMID = 21938177.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167998
  • [Keywords] NOTNLM ; Bloom Richardson's grading / Breast carcinoma / Robinson's grading / fine needle aspiration cytology
  •  go-up   go-down


1
Advertisement
4. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • We present a patient with SCAC in whom, according to PET/CT findings, the initial stage was changed from II (T2N0M0) to III A (T2N2M0).
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Balik E, Eren T, Bulut T, Büyükuncu Y, Bugra D, Yamaner S: Surgical approach to extensive hidradenitis suppurativa in the perineal/perianal and gluteal regions. World J Surg; 2009 Mar;33(3):481-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we present our experience with stage III extensive hidradenitis suppurativa cases, including our treatment methods and patient outcomes.
  • Squamous cell carcinoma was diagnosed in the specimens of one patient treated with total excision followed by the application of a rotation flap.
  • The cancer recurred after 6 months in the perianal region and immediate abdominoperineal resection was performed.
  • Despite the low incidence of accompanying squamous cell carcinoma, it is the most serious complication.
  • [MeSH-minor] Adult. Aged. Anal Canal. Buttocks. Humans. Longitudinal Studies. Male. Middle Aged. Perineum. Retrospective Studies. Skin Transplantation. Treatment Outcome. Wound Healing / physiology. Young Adult

  • Genetic Alliance. consumer health - Hidradenitis Suppurativa.
  • MedlinePlus Health Information. consumer health - Hidradenitis Suppurativa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2010 Apr;34(4):861-2; author reply 863 [20012284.001]
  • [CommentIn] World J Surg. 2009 Mar;33(3):488 [19137367.001]
  • [Cites] Arch Dermatol. 1982 Feb;118(2):101-2 [7059208.001]
  • [Cites] Plast Reconstr Surg. 1976 Jul;58(1):44-7 [935277.001]
  • [Cites] Dis Colon Rectum. 1990 Sep;33(9):731-4 [2390907.001]
  • [Cites] J Natl Med Assoc. 1982 Oct;74(10):999-1003 [7143473.001]
  • [Cites] Surg Clin North Am. 1994 Dec;74(6):1317-25 [7985067.001]
  • [Cites] Dis Colon Rectum. 1983 Oct;26(10):669-76 [6884157.001]
  • [Cites] J Surg Oncol. 1982 Jan;19(1):25-6 [7057641.001]
  • [Cites] J Am Acad Dermatol. 1984 Sep;11(3):500-2 [6384295.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):89-91 [10607326.001]
  • [Cites] Dis Colon Rectum. 1970 Nov-Dec;13(6):441-3 [5501399.001]
  • [Cites] Surgery. 2005 Oct;138(4):734-40; discussion 740-1 [16269303.001]
  • [Cites] Br J Dermatol. 2000 May;142(5):947-53 [10809853.001]
  • [Cites] Int J Colorectal Dis. 1998;13(4):164-8 [9810520.001]
  • [Cites] Am Fam Physician. 2005 Oct 15;72(8):1547-52 [16273821.001]
  • [Cites] Ann R Coll Surg Engl. 1997 Mar;79(2):83-9 [9135232.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):994-9 [8647993.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Sep;14(5):389-92 [11305381.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):944-9 [12847371.001]
  • [Cites] Ann Plast Surg. 1987 Jan;18(1):71-3 [3827135.001]
  • [Cites] Br J Surg. 1992 Sep;79(9):863-6 [1422743.001]
  • [Cites] Am Surg. 1970 Jun;36(6):331-4 [4909944.001]
  • [Cites] Br J Dermatol. 2002 Mar;146(3):409-13 [11952540.001]
  • [Cites] Histopathology. 1993 Aug;23(2):111-5 [8406382.001]
  • [Cites] J Am Acad Dermatol. 1988 May;18(5 Pt 1):1103-7 [3385029.001]
  • [Cites] Br J Plast Surg. 2000 Jul;53(5):434-6 [10876285.001]
  • [Cites] Am J Surg. 1982 Dec;144(6):668-70 [7149125.001]
  • [Cites] Int J Colorectal Dis. 1993 Sep;8(3):117-9 [8245664.001]
  • [Cites] Br J Plast Surg. 2003 Jul;56(5):451-61 [12890458.001]
  • [Cites] Br J Dermatol. 1998 Nov;139(5):906-10 [9892965.001]
  • (PMID = 19067039.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status.
  • After chemoradiotherapy, similar numbers of HIV+ and HIV- patients had grade III-IV toxicity.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


18. Saleh F, Abdeen S: Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog; 2007;6:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women.
  • Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's method, and tumour stage was determined according to the criteria set by the American Joint Committee on Cancer.
  • They were mostly grade II or III, sized 2-5 or > 5 cm, had absent or scanty tumour lymphocytes, and were stage II or III.
  • The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and cribriform were the major histological subtypes.
  • CONCLUSION: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):134-40 [15170651.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):195-208 [10068079.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):307-17 [15554559.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Kaohsiung J Med Sci. 2005 May;21(5):197-202 [15960065.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):18-21 [16029321.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2535-42 [16080489.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Acta Oncol. 1990;29(7):931-4 [1979748.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):944-8 [1988136.001]
  • [Cites] Acta Oncol. 1990;29(2):129-35 [2334566.001]
  • [Cites] Acta Oncol. 1989;28(6):807-10 [2611034.001]
  • [Cites] Aust N Z J Med. 1978 Dec;8(6):630-8 [285684.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):229-39 [6331061.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1102-9 [6491696.001]
  • [Cites] Hum Pathol. 1983 Apr;14(4):368-72 [6832775.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Breast Cancer Res Treat. 1995 Aug;35(2):201-10 [7647342.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):208-14 [7831532.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Jun;16(3):203-10 [7916848.001]
  • [Cites] Surgery. 1994 Oct;116(4):605-8; discussion 608-9 [7940156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):156-61 [8100443.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100 [8150784.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):307-11 [8447534.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2894-904 [9256133.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):97-104 [9423608.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Oncol Rep. 1999 Jan-Feb;6(1):135-8 [9864416.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Ontogenez. 1999 Mar-Apr;30(2):130-3 [10368823.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):827-34 [10463486.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):295-8 [10671674.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):81-5 [10773138.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1053-7 [12168072.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):221-36 [12462383.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):61-7 [12629055.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1321-8 [12883701.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):610-3 [1419596.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55 [15128008.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):305-19 [10066089.001]
  • (PMID = 17892570.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2169224
  •  go-up   go-down


19. Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol (Amst); 2010;33(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
  • AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
  • With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.
  • PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected.
  • RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found.
  • CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966539.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4605551
  •  go-up   go-down


20. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y, Colorectal Cancer Study Group of the Japan Clinical Oncology Group: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol; 2009 Oct;14(5):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for anal squamous cell carcinoma in Japan.
  • BACKGROUND: In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC).
  • The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
  • The target subjects were patients with stages II/III ASCC, diagnosed from January 2000 to December 2004, who were 20-80 years of age with normal major organ function and no severe complications.
  • Detailed information was obtained for 55 subjects; 25 (45%) had stage II ASCC and 30 (55%) had stage III ASCC.
  • The 3-year progression-free survival rates for all subjects and for CRT-only subjects were 67% and 77%, respectively.
  • [MeSH-major] Anus Neoplasms / therapy. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / therapy. Digestive System Surgical Procedures

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • (PMID = 19856049.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Investigator] Kondo Y; Ohtsuka K; Shiiba K; Sato T; Yoshimi F; Kotake K; Sawada T; Mochizuki H; Konishi F; Saito N; Moriya Y; Masaki T; Aoki T; Takahashi K; Hasegawa H; Kenichi S; Sumiyama Y; Sato T; Akaike M; Kudo S; Yamada T; Munakata Y; Shigeski Y; Kato T; Maeda K; Koizumi K; Monden M; Ohue M; Higashino M; Tanigawa M; Fukunaga M; Kato T; Okamura S; Kimura H; Okajima M; Takakura N; Tanada M; Shirouzu K; Kitano S
  •  go-up   go-down


21. Rabbani AN, Zlotecki RA, Kirwan J, George TJ Jr, Morris CG, Rout WR, Mendenhall WM: Definitive radiotherapy for squamous cell carcinoma of the anal canal. Am J Clin Oncol; 2010 Feb;33(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy for squamous cell carcinoma of the anal canal.
  • PURPOSE: To review the outcomes of definitive radiotherapy (RT) alone or combined with chemotherapy (CT) in the treatment of squamous cell carcinoma of the anal canal.
  • Distribution according to T stage was: T1, 11 (16%); T2, 29 (42%); T3, 21 (30%); and T4, 8 (12%).
  • Distribution according to N stage was: N0, 53 (77%); N1, 3 (4%); N2, 7 (10%); and N3, 6 (9%).
  • The 5-year cause-specific and overall survival rates were: stage I, 100% and 64%; stage II, 86% and 70%; stage III, 80% and 76%; and overall, 87% and 71%, respectively.
  • [MeSH-major] Anal Canal / radiation effects. Antineoplastic Agents / therapeutic use. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Neoplasm Recurrence, Local / diagnosis


22. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


24. Elgaili EM, Abuidris DO, Rahman M, Michalek AM, Mohammed SI: Breast cancer burden in central Sudan. Int J Womens Health; 2010;2:77-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer burden in central Sudan.
  • Breast cancer is a worldwide disease resulting in many deaths.
  • Although breast cancer incidence is lower in Sub-Saharan African countries than in developed countries, African women are more likely than women in the developed world to be diagnosed at later stages of the disease and, thus, are more likely to die from it.
  • This descriptive study was undertaken to shed light on the type, stage and age distribution of breast cancer at diagnosis in women living in central Sudan encompassing al-Gezira, Blue Nile, White Nile, and Sennar States.
  • Cases comprised 1255 women from central Sudan diagnosed with breast cancer and referred to and treated at Institute of Nuclear Medicine, Molecular Biology, and Oncology, from January 1999 to December 2006.
  • Invasive ductal carcinoma was the most common pathology (82%) and women presenting with stage III or higher tumors that had already metastasized, while ductal carcinoma in situ was the least prevalent (0.5%) finding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21072300.001).
  • [ISSN] 1179-1411
  • [Journal-full-title] International journal of women's health
  • [ISO-abbreviation] Int J Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2971742
  • [Keywords] NOTNLM ; Africa / epidemiology / estrogen receptor / female breast cancer / progesterone receptor
  •  go-up   go-down


25. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy


26. Zuo ZG, Song HY, Xu C, Li J, Ni SC, Chen SQ: [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors]. Zhonghua Wai Ke Za Zhi; 2009 Jul 1;47(13):988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors].
  • OBJECTIVE: To study the combination of trans-anal intersphincteric resection and transabdominal total mesorectal excision for anus-retained ultra-low rectal tumors.
  • METHODS: Clinical data of 34 ultra-low rectal tumor patients without external anal sphincter involved, who underwent the combination surgery, were retrospectively analyzed.
  • For pathological types, there were 23 cases of adenocarcinoma (9 well differentiated and 14 moderately differentiated), 1 papillary carcinoma, 2 rectal stromal tumor, 5 rectal villous adenoma with neoplasia and 3 giant villous adenoma.
  • For pathological stages, there were 18 cases at stage pTNM I, 5 at IIA, 1 at IIB, 4 at IIIA, 1 at III and for T grading, there were 15 cases at stage T1, 5 at T2, 8 at T3, 1 at T4.
  • Because of the dysfunction of bowel control, bowel frequency varied from 3 to 12 in the early stage after operation, but with the recovery of anus function, bowel frequency decreased and ranged form 1 to 5 times a day and the time of formed bowel control could be more than 5 min in 6-12 months after operation.
  • However, patients underwent total resection of internal anal sphincter still suffered from incontinence of loose stool after 1 year.
  • CONCLUSION: The combination of trans-anal ISR and trans-abdominal TME for anus-retained ultra low rectal tumor is not only coincident with radical tumor principle but also retains the function of anus, on the premise of the strict indication.
  • [MeSH-major] Anal Canal / surgery. Mesentery / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957808.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL: Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation. Cancer Lett; 2010 Apr 1;290(1):49-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
  • The present study identifies anti-thrombin III (ATIII) as an endogenous MIF binding protein, which reduces MIF biological activity.
  • Serum MIF in bladder cancer patients (TCC stage II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder cancer patient serum.
  • These data suggest that increased circulating levels of bioactive MIF are present in bladder cancer patient serum.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Nat Med. 2000 Feb;6(2):164-70 [10655104.001]
  • [Cites] Mediators Inflamm. 2009;2009:535348 [19325914.001]
  • [Cites] Transplantation. 2001 Jun 27;71(12):1777-83 [11455258.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4015-20 [12010802.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Trends Cardiovasc Med. 2002 Nov;12(8):331-8 [12536119.001]
  • [Cites] Immunol Cell Biol. 2003 Apr;81(2):137-43 [12631237.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] J Endotoxin Res. 2003;9(2):119-23 [12803886.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13729-37 [14736878.001]
  • [Cites] BMC Cancer. 2004 Jul 12;4:34 [15248897.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1504-9 [15371880.001]
  • [Cites] Am J Clin Pathol. 1978 Feb;69(2):194-5 [629228.001]
  • [Cites] J Clin Pathol. 1979 Jan;32(1):21-5 [429575.001]
  • [Cites] Thromb Haemost. 1981 Aug 28;46(2):500-3 [7302888.001]
  • [Cites] J Urol. 1982 Jul;128(1):72-4 [7109075.001]
  • [Cites] Am J Med. 1989 Sep 11;87(3B):10S-14S [2552799.001]
  • [Cites] Thromb Haemost. 1996 Dec;76(6):897-901 [8972008.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19393-400 [9235938.001]
  • [Cites] Int J Hematol. 1998 Jul;68(1):67-78 [9713170.001]
  • [Cites] BMC Cancer. 2005;5:73 [16000172.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36541-4 [16115897.001]
  • [Cites] Eur J Immunol. 2005 Dec;35(12):3405-13 [16224818.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):60-5 [16440418.001]
  • [Cites] J Urol. 2006 Apr;175(4):1523-8 [16516040.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3100-12 [17496909.001]
  • [Cites] Mol Endocrinol. 2007 Jun;21(6):1267-80 [17389748.001]
  • [Cites] Autoimmun Rev. 2007 Nov;7(1):8-11 [17967718.001]
  • [Cites] Electrophoresis. 2007 Dec;28(23):4302-10 [18041032.001]
  • [Cites] Intensive Care Med. 2008 Feb;34(2):361-7 [17940748.001]
  • [Cites] Inflamm Res. 2008 Feb;57(2):45-50 [18288453.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):665-75 [18064633.001]
  • [Cites] Oncology. 2008;75(3-4):127-33 [18791328.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3533-6 [18982159.001]
  • [Cites] J Cell Biochem. 2008 Dec 1;105(5):1279-88 [18821572.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1922-32 [19188446.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1117-23 [10666179.001]
  • (PMID = 19762145.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK075059; United States / NIAID NIH HHS / AI / R01 AI042310-06; United States / NIDDK NIH HHS / DK / DK075059; United States / NIAID NIH HHS / AI / R01 AI042310; United States / NIDDK NIH HHS / DK / DK075059-02; United States / NIDDK NIH HHS / DK / R21 DK075059-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Multiprotein Complexes; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS146096; NLM/ PMC2832085
  •  go-up   go-down


28. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • Ten patients (18 percent) had an American Society of Anesthesiologists' classification of III.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • Of those who underwent curative resection (Stages I-III), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


29. Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, Pfisterer J, du Bois A: Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch; 2009 Mar;454(3):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
  • While there is no doubt that histologic grading is applicable in early stage ovarian carcinoma, it is still in controversial discussion concerning advanced stage ovarian carcinoma.
  • It was the aim of this study to assess the three most widely used grading systems for ovarian carcinoma in terms of prognostic significance, concordance rates, and reproducibility in a large number of advanced stage ovarian carcinomas of all types after standardized chemotherapy.
  • Representative hematoxylin and eosin slides from 334 cases of stage IIB-IV ovarian carcinoma (prospective randomized, multi-center, phase III study) were used.
  • Grading of advanced stage ovarian carcinomas was of no value for estimation of prognosis in this homogeneously treated patient group.
  • [MeSH-minor] Aged. Clinical Trials, Phase III as Topic. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Feb;52(3):393-5 [18081817.001]
  • [Cites] Cancer. 1980 Feb;45(3):572-81 [7353206.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):117-23 [6693048.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):447-52 [12798710.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Dec;8(4):354-7 [3814303.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):348-53 [11109164.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):67-71 [16516280.001]
  • [Cites] Acta Obstet Gynecol Scand. 1971;50(1):1-7 [5558593.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [18317226.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):52-6 [12496698.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):147-55 [2714932.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Obstet Gynaecol Res. 2001 Dec;27(6):313-8 [11794816.001]
  • (PMID = 19172293.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


30. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y: Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci; 2010 Dec;55(12):3576-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.
  • BACKGROUND: Alpha-fetoprotein (AFP) has been widely used as a diagnostic master for hepatocellular carcinoma (HCC), and the fucosylated fraction of AFP (AFP-L3) has been reported to be a specific marker for HCC.
  • The positivity rates for μ-TAS AFP-L3 were higher at each tumor stage than those of LiBASys AFP-L3 (μ-TAS/LiBASys: stage I, 44.2%/16.3%; stage II, 52.9%/37.5%; stage III, 66.4%/44.5%; stage IV, 82.8%/65.5%).
  • CONCLUSIONS: μ-TAS AFP-L3 is more sensitive for discriminating HCC than the conventional LiBASys AFP-L3, particularly in subgroups with lower AFP concentrations and early-stage HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Immunoassay / methods. Liver Neoplasms / diagnosis. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 2008 Apr;29(7):1399-406 [18384019.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Dec;16(12):1378-83 [11851836.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3028-33 [10520864.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2076-82 [9827711.001]
  • [Cites] Hepatology. 1993 Jan;17(1):50-2 [7678576.001]
  • [Cites] J Gastroenterol. 2003;38(3):207-15 [12673442.001]
  • [Cites] Anal Biochem. 2009 May 15;388(2):306-11 [19250915.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1344-50 [4174340.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12):2452-6 [9860408.001]
  • [Cites] J Gastroenterol. 2007 Dec;42(12):962-8 [18085353.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5419-23 [7693340.001]
  • [Cites] J Hepatol. 1999 Jan;30(1):125-30 [9927159.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):769-74 [2448024.001]
  • [Cites] Cancer. 1970 May;25(5):1091-8 [5443731.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):240-4 [11246354.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1518-27 [17133456.001]
  • [Cites] Hepatol Res. 2007 Nov;37(11):914-22 [17610501.001]
  • [Cites] Am J Clin Pathol. 1999 Jun;111(6):811-6 [10361518.001]
  • [Cites] Anal Chem. 1998 Mar 1;70(5):954-7 [9511471.001]
  • (PMID = 20407827.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Plant Lectins; 0 / alpha-Fetoproteins
  •  go-up   go-down


31. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers. Ann Surg Oncol; 2008 Dec;15(12):3478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We tried to evaluate the clinicopathological characteristics of rectosigmoid cancer compared with those of sigmoid and rectal cancer.
  • METHODS: We collected data on patients who underwent curative resections for sigmoid (399; SC group), rectosigmoid (175; RS group), and upper rectal cancer (453; RA group) between June 1996 and December 2007.
  • RESULTS: The mean distance from the anal verge was 12.5 cm for rectosigmoid cancer, 13 cm for sigmoid cancer, and 9.8 cm for rectal cancer.
  • For stage III disease, the local recurrence rate was significantly higher in the RA group; the disease-free survival rate was higher in the SC group, and the RS group showed results similar to those of the RA group.
  • CONCLUSION: Clinicopathological characteristics of rectosigmoid cancer were similar to those of sigmoid or rectal cancer.
  • For lymphatic spreads, it was different from sigmoid or rectal cancer and more frequently metastasized to pararectal nodes.
  • Oncologic results were slightly unfavorable to sigmoid colon, and showed data similar to those of rectal cancer.
  • Therefore, rectosigmoid cancer was a "real" classification of colorectal cancer with unique lymphatic spread.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Carcinoma, Signet Ring Cell / secondary. Lymph Nodes / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):346-7 [19841983.001]
  • (PMID = 18830668.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


33. Rubio CA, Nilsson PJ: Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications. Anticancer Res; 2008 Jul-Aug;28(4C):2469-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications.
  • BACKGROUND: It has been claimed that patients with squamous cell carcinoma of the anal canal (SCCAC) showing intraepithelial lymphocytes have a poor prognosis.
  • All these 8 patients with SCCAC/HTIL had clinical stage II and III while these stages comprised 83% of the remaining SCCAC cases.
  • CONCLUSION: Despite the 8 SCCAC/HTIL patients having a more advanced clinical stage than the remaining 269 SCCAC patients, these 8 patients had longer survival.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphocytes, Tumor-Infiltrating / pathology. Lymphocytosis / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751436.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement